放射线联合p53基因及内皮抑素治疗小鼠前列腺癌皮下移植瘤

Objective To test the hypothesis that p53 gene therapy combined with endostatin can enhance tumor response to radiation therapy of RM-1 mouse xenograft prostate cancer and to investigate its mechanism. Methods A mouse prostate cancer model was established. Then mice with xenograft tumor were randomly divided into group A (control), B (radiation), C (radiation and rAdp53), D (radiation and rh-endostatin) and E (radiation and rAdp53 and rh-endostatin). On day 1, rAdp53 was injected intra-tumorously with 1 × 1010 vp per animal to group C and E. From day 1 to 14, rh-endostatin was given 15 mg/kg intraperitoneally daily to group D and E. On day 4 single fraction of 15 Gy was given to tumors in groups B, C, D and E. Normal saline was injected intra-tumorously or intraperitoneaUy accordingly as control. No treatment was done to group A. Tumor volume was measured daily. Samples were collected on Days 5, 10 and 15. Ki67, CD31, p53 and VEGF were detected by means of immunohistochemistry. Results (1) Radiation alone, radiation combined with intra-tumorous injection of Adp53 and/or intraperitoneal injection of rh-endostatin resulted in tumor growth arrest of RM-1 cells in vivo (P = 0.000). Radiation combined with both rAdp53 and rh-endostatin was the most effective treatment (P < 0.05). (2) All the four treatment groups had a decreased expression of mutant type P53 (P = 0.000). The expression of Ki67 in groups B and C were equal (P 0.05) and increasing (P = 0.000), respectively. Group D had a up-down-up curve (P < 0.05), but group E had a up-down one. On day 5 the expresion of VEGF in group E was the lowest (P < 0.05). An increased expression of MVD compared with the control was shown, and MVD in groups C, D and E were always higher than that in the control (P < 0.05). Conclusions The limitation of radiotherapy could be overcome by combination with beth p53 gene therapy and endostatin on the growth of mouse prostate cancer cell. Radiation, rAdp53 and endostatin have their own role but they can be interacted with each other.     

原发性肝癌治疗的新手段——基因治疗

肝细胞癌（HCC）对化疗不敏感，手术切除和肝移植是治疗HCC的有效方法。动脉栓塞术、乙醇注射、射频消融、微波固化、激光热疗、冷冻等局部治疗手段对于无法行手术切除的患者有一定的效果．但复发较常见。且远期存活率无明显提高。近年来，一种新型的治疗手段——基因治疗引起了越来越多学者的关注。现简述HCC发生的分子机制及基因治疗现状。     

病理性瘢痕基因治疗的研究进展

病理性瘢痕一直是整形外科治疗中的一个难题，是真皮组织过度增生及细胞基质成分大量沉积的结果，表现为高出皮肤表面并影响外观与功能的异常增生，也称为异常瘢痕。临床上分为增生性瘢痕（hypertrophic scar，HS）及瘢痕疙瘩（keloid,K），目前尚无理想的治疗方法。笔者现从基因治疗的角度出发。探讨病理性瘢痕基因治疗的研究进展及前景。     

综述列题

Apoptin-肿瘤基因治疗的新选择；BRLF1-EBV的一种立即早期基因的研究进展；E-选择素及其配体与肿瘤关系的研究进展；gp96与肿瘤免疫研究进展；IL-12抗肿瘤基因治疗的研究进展；p73基因与人类肿瘤的研究进展；RNA千扰技术的应用；Survivin基因及其与肿瘤靶向治疗；T淋巴瘤侵袭转移诱导因子1与肿瘤侵袭转移的研究进展；表皮生长因子受体信号通路及其靶向肿瘤治疗；单核苷酸多态性与肿瘤转移的关系；反应停抗肿瘤作用研究进展。[编者按]     

同种异体血管移植及其基因治疗

基因修饰的血管内皮细胞体外培养，种植于经冻干辐照的异体血管，可以从根本上减轻异体血管移植的排斥反应和提高其远期通畅率。     

多药耐药基因转染骨髓造血细胞移植小鼠的安全性研究

目的 探讨多药耐药基因(mdrl)转染骨髓造血细胞移植后,其在体内分布和安全性.方法 骨髓造血细胞转染mdrl基因后移植入BALB/C鼠,免疫组织化学和RT.PCR观察mdrl基因在骨髓、外周血及重要脏器的表达;监测外周血白细胞变化及重要脏器病检分析其安全性.结果 P-糖蛋白(P-gP)在骨髓表达率随时间降低,各时间组差异无统计学意义(x2=3.74,P＞0.05),在外周血表达第2月最高,为(9.95±1.84)%,各时间组差异无统计学意义(x2=2.31,P＞0.05),在重要脏器无表达;移植未转染组与移植转染组外周血白细胞计数至移植60 d后,两者差异有统计学意义(t=6.173,P＜0.05),病检除肝和肾有炎性渗出和水肿病变外,其余无异常.结论 mdrl基因在骨髓和外周血有持续较高表达,在重要脏器无表达;mdrl基因转染对造血恢复及重要脏器无明显影响.     

重组人骨形态发生蛋白4基因腺相关病毒载体对兔骨髓基质干细胞生物学行为的影响

目的应用重组人骨形态发生蛋白4基因腺相关病毒载体(AAV-hBMP4)转染兔骨髓基质干细胞(BMSCs),观察其对BMSCs生物学行为的影响,从而为骨组织工程寻找理想的病毒载体及种子细胞。方法全骨髓法培养兔BMSCs,按感染复数(MOI)值不同设定为四组,分别转染兔BMSCs,观察病毒量对细胞形态的影响。选取影响最小的MOI值,进行后续实验。转染兔BMSCs,MTT法描记细胞生长曲线,观察AAV对细胞增殖活性的影响。以重组增强型绿色荧光蛋白基因的腺相关病毒载体(AAV-EGFP)为参照,行流式细胞仪检测,计算转染效率。AAV-hBMP4与对照病毒AAV-EGFP分别转染细胞,观察细胞形态,行碱性磷酸酶(ALP)染色、Von Kossa染色及ALP含量测定,观察成骨活性。兔肌袋实验观察异位成骨情况。结果MOI值为5×10~4 vg/cell时,AAV对细胞形态影响最小,以此值进行后续实验。AAV转染后,细胞增殖活性良好,转染效率为55％～65％。AAV-hBMP4转染后,细胞形态呈现典型的成骨改变,ALP染色及Von Kossa染色均出现成骨的特征性改变,而AAV-EGFP组无上述改变。细胞上清ALP含量测定显示,实验组ALP含量显著增高,与对照组比较差异有统计学意义(t=218．65,P＜0．01)。兔肌袋实验术后4周组织学检测可见大量钙盐沉积,矿化结节形成。结论AAV-hBMP4转染效率高,对BMSCs的增殖活性影响小,AAV-hBMP4转染的BMSCs可望成为组织工程化骨的理想种子细胞。     

基因治疗在心脏外科的作用

尽管基因治疗在实验研究方面已做了大量的工作 ,但实际上临床治疗成功的尚不多。现复习这一领域的近期文献 ,并讨论基因治疗的一些限制和潜在的问题 ,强调在心脏外科作基因治疗临床试验之前必须提请考虑的问题和规则。